Isabelle Demeestere

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3924324/publications.pdf

Version: 2024-02-01

100 papers

5,566 citations

38 h-index 72 g-index

105 all docs $\begin{array}{c} 105 \\ \\ \text{docs citations} \end{array}$

105 times ranked 3780 citing authors

#	Article	lF	Citations
1	Risk of contamination of semen, vaginal secretions, follicular fluid and ovarian medulla with SARS-CoV-2 in patients undergoing ART. Human Reproduction, 2022, 37, 235-241.	0.9	16
2	A retrospective study evaluating the impact of scattering radiation from imaging procedures on oocyte quality during ovarian stimulation for fertility preservation in young breast cancer patients. Breast Cancer Research and Treatment, 2022, 192, 123-130.	2.5	0
3	Fresh and cryopreserved ovarian tissue transplantation for preserving reproductive and endocrine function: a systematic review and individual patient data meta-analysis. Human Reproduction Update, 2022, 28, 400-416.	10.8	43
4	Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review. Human Reproduction Update, 2022, 28, 417-434.	10.8	40
5	Follicle Activation by Physical Methods and Clinical Applications. , 2022, , 263-278.		2
6	Ovarian toxicity of carboplatin and paclitaxel in mouse carriers of mutation in BRIP1 tumor suppressor gene. Scientific Reports, 2022, 12, 1658.	3.3	4
7	First live birth after fertility preservation using vitrification of oocytes in a woman with mosaic Turner syndrome. Journal of Assisted Reproduction and Genetics, 2022, 39, 543-549.	2.5	18
8	Abstract PD5-05: Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTTO trial. Cancer Research, 2022, 82, PD5-05-PD5-05.	0.9	0
9	Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis. Human Reproduction, 2022, 37, 954-968.	0.9	41
10	Reply: Risk of contamination with SARS-CoV-2 in ART. Human Reproduction, 2022, , .	0.9	0
11	Risk of gonadotoxicity with immunotherapy and targeted agents remains an unsolved but crucial issue. European Journal of Clinical Investigation, 2022, 52, e13779.	3.4	7
12	Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTTO trial Journal of Clinical Oncology, 2022, 40, 12084-12084.	1.6	0
13	Methods of Ovarian Tissue Cryopreservation: Slow Freezing. , 2022, , 89-98.		0
14	Let-7a mimic transfection reduces chemotherapy-induced damage in a mouse ovarian transplantation model. Scientific Reports, 2022, 12, .	3.3	8
15	Ovarian tissue cryopreservation and transplantation in patients with central nervous system tumours. Human Reproduction, 2021, 36, 1296-1309.	0.9	11
16	Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncology, The, 2021, 22, e45-e56.	10.7	91
17	Cancer survivorship: Reproductive health outcomes should be included in standard toxicity assessments. European Journal of Cancer, 2021, 144, 310-316.	2.8	34
18	Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncology, The, 2021, 22, e68-e80.	10.7	37

#	Article	IF	Citations
19	Use of GnRH Analogs for Prevention of Chemotherapy-Induced Gonadotoxicity. , 2021, , 171-181.		O
20	Anti-Mýllerian hormone (AMH) as a marker of ovarian reserve and premature ovarian insufficiency (POI) in children and women with cancer: A systematic review Journal of Clinical Oncology, 2021, 39, e24057-e24057.	1.6	0
21	Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data. Journal of Clinical Oncology, 2021, 39, 2016-2024.	1.6	36
22	Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011). Journal of Clinical Oncology, 2021, 39, 3251-3260.	1.6	17
23	O-179 Safety of ovarian tissue cryopreservation and transplantation in patients with central nervous system cancers. Human Reproduction, 2021, 36, .	0.9	O
24	Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. Journal of Clinical Oncology, 2021, 39, 3293-3305.	1.6	70
25	Circulating Tumor DNA to Interrogate the Safety of Letrozole-Associated Controlled Ovarian Stimulation for Fertility Preservation in Breast Cancer Patients. Frontiers in Oncology, 2021, 11, 686625.	2.8	5
26	Impact of ARTs on oncological outcomes in young breast cancer survivors. Human Reproduction, 2021, 36, 381-389.	0.9	7
27	Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer. ESMO Open, 2021, 6, 100300.	4.5	9
28	Interaction between PI3K/AKT and Hippo pathways during in vitro follicular activation and response to fragmentation and chemotherapy exposure using a mouse immature ovary model. Biology of Reproduction, 2020, 102, 717-729.	2.7	39
29	Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelinesâ€. Annals of Oncology, 2020, 31, 1664-1678.	1.2	243
30	ESHRE guideline: female fertility preservationâ€. Human Reproduction Open, 2020, 2020, hoaa052.	5.4	282
31	Implications of Nonphysiological Ovarian Primordial Follicle Activation for Fertility Preservation. Endocrine Reviews, 2020, 41, 847-872.	20.1	35
32	Efficacy and Safety of Controlled Ovarian Stimulation With or Without Letrozole Co-administration for Fertility Preservation: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2020, 10, 574669.	2.8	48
33	The role of microRNAs in ovarian function and the transition toward novel therapeutic strategies in fertility preservation: from bench to future clinical application. Human Reproduction Update, 2020, 26, 174-196.	10.8	15
34	Fertility preservation counselling for childhood cancer survivors. Lancet Oncology, The, 2020, 21, 329-330.	10.7	3
35	Overview of Fertility Preservation Approaches in Cancer Patients., 2020,, 25-42.		0
36	Impact of Taxanes, Endocrine Therapy, and Deleterious Germline BRCA Mutations on Anti-mýllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based Chemotherapy. Frontiers in Oncology, 2019, 9, 575.	2.8	40

#	Article	IF	CITATIONS
37	MicroRNA profiling and identification of let-7a as a target to prevent chemotherapy-induced primordial follicles apoptosis in mouse ovaries. Scientific Reports, 2019, 9, 9636.	3.3	22
38	Ultrastructure and intercellular contact-mediated communication in cultured human early stage follicles exposed to mTORC1 inhibitor. Molecular Human Reproduction, 2019, 25, 706-716.	2.8	10
39	Answer to Controversy: miR-10a Replacement Approaches Do Not Offer Protection against Chemotherapy-Induced Gonadotoxicity in Mouse Model. International Journal of Molecular Sciences, 2019, 20, 4958.	4.1	4
40	Oncofertility: Pharmacological Protection and Immature Testicular Tissue (ITT)-Based Strategies for Prepubertal and Adolescent Male Cancer Patients. International Journal of Molecular Sciences, 2019, 20, 5223.	4.1	15
41	Fertility and hormone preservation and restoration for female children and adolescents receiving gonadotoxic cancer treatments: A systematic review. Journal of Pediatric Surgery, 2019, 54, 2200-2209.	1.6	51
42	Challenges of fertility preservation in nonâ€oncological diseases. Acta Obstetricia Et Gynecologica Scandinavica, 2019, 98, 638-646.	2.8	22
43	Fertility, sexuality and cancer in young adult women. Current Opinion in Oncology, 2019, 31, 259-267.	2.4	20
44	Letrozole-associated controlled ovarian hyperstimulation in breast cancer patients versus conventional controlled ovarian hyperstimulation in infertile patients: assessment of oocyte quality related biomarkers. Reproductive Biology and Endocrinology, 2019, 17, 3.	3.3	27
45	Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients. Reproductive BioMedicine Online, 2019, 38, 835-844.	2.4	29
46	Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application. Cancer Treatment Reviews, 2019, 72, 65-77.	7.7	83
47	Oncofertility counselling in premenopausal women with HER2-positive breast cancer. Oncotarget, 2019, 10, 926-929.	1.8	6
48	The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy issues in young breast cancer patients. European Journal of Cancer, 2018, 92, S22.	2.8	1
49	Both in vivo FSH depletion and follicular exposure to Gonadotrophin-releasing hormone analogues in vitro are not effective to prevent follicular depletion during chemotherapy in mice. Molecular Human Reproduction, 2018, 24, 221-232.	2.8	15
50	Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients. Annals of Oncology, 2018, 29, 237-243.	1.2	90
51	Another step towards improving oncofertility counselling of young women with Hodgkin's lymphoma. Lancet Oncology, The, 2018, 19, 1264-1266.	10.7	6
52	The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. Breast, 2018, 42, 41-49.	2.2	75
53	Dynamics of PI3K and Hippo signaling pathways during in vitro human follicle activation. Human Reproduction, 2018, 33, 1705-1714.	0.9	144
54	Methods of controlled ovarian stimulation for embryo/oocyte cryopreservation in breast cancer patients. Expert Review of Quality of Life in Cancer Care, 2017, 2, 47-59.	0.6	13

#	Article	IF	CITATIONS
55	Controversies about fertility and pregnancy issues in young breast cancer patients: current state of the art. Current Opinion in Oncology, 2017, 29, 243-252.	2.4	68
56	Outcomes of immature oocytes collected from ovarian tissue for cryopreservation in adult and prepubertal patients. Reproductive BioMedicine Online, 2017, 34, 575-582.	2.4	70
57	Fertility and pregnancy issues in BRCA -mutated breast cancer patients. Cancer Treatment Reviews, 2017, 59, 61-70.	7.7	68
58	Does oocyte donation compared with autologous oocyte IVF pregnancies have a higher risk of preeclampsia?. Reproductive BioMedicine Online, 2017, 34, 11-18.	2.4	27
59	Reply to M. Lambertini et al. Journal of Clinical Oncology, 2017, 35, 805-806.	1.6	1
60	Assessment of ovarian reserve and fertility preservation strategies in children treated for cancer. Minerva Obstetrics and Gynecology, 2017, 69, 57-67.	1.0	8
61	Viable Options for Fertility Preservation in Breast Cancer Patients: A Focus on Latin America. Revista De Investigacion Clinica, 2017, 69, 103-113.	0.4	9
62	Response to †Is it safe to perform a controlled ovarianÂstimulation for assisted reproduction in youngÂbreastÂcancer survivors?'. European Journal of Cancer, 2016, 54, 165-166.	2.8	2
63	Pregnancy Rate and Preservation of Cyclic Ovarian Function With Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy—Reply. JAMA Oncology, 2016, 2, 546.	7.1	3
64	No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial. Journal of Clinical Oncology, 2016, 34, 2568-2574.	1.6	199
65	AMH mutations with reduced in vitro bioactivity are related to premature ovarian insufficiency. Human Reproduction, 2015, 30, 1196-1202.	0.9	50
66	Live birth after autograft of ovarian tissue cryopreserved during childhood: Figure 1. Human Reproduction, 2015, 30, 2107-2109.	0.9	310
67	Pregnancy following breast cancer using assisted reproduction and its effect on long-term outcome. European Journal of Cancer, 2015, 51, 1490-1496.	2.8	64
68	Evaluation of quantitative polymerase chain reaction markers for the detection of breast cancer cells in ovarian tissue stored for fertility preservation. Fertility and Sterility, 2015, 104, 410-417.e4.	1.0	11
69	Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients. Human Reproduction, 2015, 30, 2184-2189.	0.9	45
70	Folliculogenesis Is Not Fully Inhibited during GnRH Analogues Treatment in Mice Challenging Their Efficiency to Preserve the Ovarian Reserve during Chemotherapy in This Model. PLoS ONE, 2015, 10, e0137164.	2.5	16
71	Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials. Cancer Treatment Reviews, 2014, 40, 675-683.	7.7	169
72	Follicle-stimulating hormone regulates expression and activity of epidermal growth factor receptor in the murine ovarian follicle. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16778-16783.	7.1	80

#	Article	IF	Citations
73	Safety and usefulness of cryopreservation of ovarian tissue to preserve fertility: a 12-year retrospective analysis. Human Reproduction, 2014, 29, 1931-1940.	0.9	125
74	Reply to Z. Blumenfeld et al. Journal of Clinical Oncology, 2013, 31, 3722-3723.	1.6	1
75	Gonadotropin-Releasing Hormone Agonist for the Prevention of Chemotherapy-Induced Ovarian Failure in Patients With Lymphoma: 1-Year Follow-Up of a Prospective Randomized Trial. Journal of Clinical Oncology, 2013, 31, 903-909.	1.6	108
76	Safety of Ovarian Tissue Autotransplantation for Cancer Patients. Obstetrics and Gynecology International, 2012, 2012, 1-6.	1.3	17
77	Multiple Approaches for Individualized Fertility Protective Therapy in Cancer Patients. Obstetrics and Gynecology International, 2012, 2012, 1-12.	1.3	18
78	Fertility Preservation in Female Cancer Patients. Obstetrics and Gynecology International, 2012, 2012, 1-2.	1.3	7
79	Follicle-Stimulating Hormone Accelerates Mouse Oocyte Development In Vivo1. Biology of Reproduction, 2012, 87, 3, 1-11.	2.7	29
80	In-vitro maturation of human oocytes: before or after vitrification?. Journal of Assisted Reproduction and Genetics, 2012, 29, 507-512.	2.5	67
81	Children born after autotransplantation of cryopreserved ovarian tissue. A review of 13 live births. Annals of Medicine, 2011, 43, 437-450.	3.8	309
82	Vitrification of in vitro matured oocytes collected from antral follicles at the time of ovarian tissue cryopreservation. Reproductive Biology and Endocrinology, 2011, 9, 150.	3.3	77
83	Anonymity and secrecy options of recipient couples and donors, and ethnic origin influence in three types of oocyte donation. Human Reproduction, 2011, 26, 382-390.	0.9	63
84	Pregnancy outcome after oocyte donation in patients with Turner's syndrome and partial X monosomy. Human Reproduction, 2011, 26, 2061-2068.	0.9	49
85	Birth of a second healthy girl more than 3 years after cryopreserved ovarian graft. Human Reproduction, 2010, 25, 1590-1591.	0.9	58
86	Nucleoside Analog Stavudine Depletes Mitochondrial DNA with No Organelle Loss in Mouse Oocytes. Current HIV Research, 2010, 8, 127-133.	0.5	3
87	Variants of the BMP15 gene in a cohort of patients with premature ovarian failure. Human Reproduction, 2010, 25, 1581-1587.	0.9	79
88	Orthotopic and heterotopic ovarian tissue transplantation. Human Reproduction Update, 2009, 15, 649-665.	10.8	234
89	GnRH analogue for chemotherapy-induced ovarian damage: too early to say?. Fertility and Sterility, 2009, 92, e33.	1.0	12
90	Fertility Preservation: Successful Transplantation of Cryopreserved Ovarian Tissue in a Young Patient Previously Treated for Hodgkin's Disease. Oncologist, 2007, 12, 1437-1442.	3.7	346

#	ARTICLE	IF	CITATION
91	Stable serum levels of anti-Mullerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. Human Reproduction, 2007, 22, 1837-1840.	0.9	254
92	Ovarian function and spontaneous pregnancy after combined heterotopic and orthotopic cryopreserved ovarian tissue transplantation in a patient previously treated with bone marrow transplantation: Case Report. Human Reproduction, 2006, 21, 2010-2014.	0.9	232
93	OPTIONS TO PRESERVE FERTILITY BEFORE ONCOLOGICAL TREATMENT: CRYOPRESERVATION OF OVARIAN TISSUE AND ITS CLINICAL APPLICATION. Acta Clinica Belgica, 2006, 61, 259-263.	1.2	10
94	Impact of various endocrine and paracrine factors on in vitro culture of preantral follicles in rodents. Reproduction, 2005, 130, 147-156.	2.6	93
95	Premature ovarian aging in mice deficient for <i>Gpr3</i> . Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 8922-8926.	7.1	128
96	Effect of Insulin-Like Growth Factor-I During Preantral Follicular Culture on Steroidogenesis, In Vitro Oocyte Maturation, and Embryo Development in Mice1. Biology of Reproduction, 2004, 70, 1664-1669.	2.7	79
97	Preliminary experience of ovarian tissue cryopreservation procedure: alternatives, perspectives and feasibility. Reproductive BioMedicine Online, 2003, 7, 572-579.	2.4	49
98	Effect of preantral follicle isolation technique on in-vitro follicular growth, oocyte maturation and embryo development in mice. Human Reproduction, 2002, 17, 2152-2159.	0.9	63
99	Hardening of zona pellucida of mouse oocytes and embryos in vivo and in vitro. International Journal of Fertility and Women's Medicine, 1997, 42, 219-22.	0.4	12
100	Unpredictable cases of complicated ovarian hyperstimulation in IVF. International Journal of Fertility and Women's Medicine. 1997, 42, 268-70.	0.4	5